English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Select site language

Pemetrexed Fresenius Kabi (pemetrexed) – Package leaflet - L01BA04

Updated on site: 09-Oct-2017

Medication namePemetrexed Fresenius Kabi
ATC CodeL01BA04
Substancepemetrexed
ManufacturerFresenius Kabi Oncology Plc

Package leaflet: Information for the user

Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion pemetrexed

Read all of this leaflet carefully before you start receiving this medicine because it contains important information for you.

-Keep this leaflet. You may need to read it again.

-If you have further questions, please ask your doctor or pharmacist.

-If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1.What Pemetrexed Fresenius Kabi is and what it is used for

2.What you need to know before you use Pemetrexed Fresenius Kabi

3.How to use Pemetrexed Fresenius Kabi

4.Possible side effects

5.How to store Pemetrexed Fresenius Kabi

6.Contents of the pack and other information

1.What Pemetrexed Fresenius Kabi is and what it is used for

Pemetrexed Fresenius Kabi is a medicine used in the treatment of cancer.

Pemetrexed Fresenius Kabi is given in combination with cisplatin, another anti-cancer medicine, as treatment for malignant pleural mesothelioma, a form of cancer that affects the lining of the lung, to patients who have not received prior chemotherapy.

Pemetrexed Fresenius Kabi is also given in combination with cisplatin for the initial treatment of patients with advanced stage of lung cancer.

Pemetrexed Fresenius Kabi can be prescribed to you if you have lung cancer at an advanced stage if your disease has responded to treatment or it remains largely unchanged after initial chemotherapy.

Pemetrexed Fresenius Kabi is also a treatment for patients with advanced stage of lung cancer whose disease has progressed after other initial chemotherapy has been used.

2.What you need to know before you use Pemetrexed Fresenius Kabi

Do not use Pemetrexed Fresenius Kabi

-if you are allergic to pemetrexed or any of the other ingredients of this medicine (listed in section 6).

-if you are breast-feeding; you must discontinue breast-feeding during treatment with Pemetrexed Fresenius Kabi.

-if you have recently received or are about to receive a vaccine against yellow fever.

Warnings and precautions

Talk to your doctor or hospital pharmacist before receiving Pemetrexed Fresenius Kabi.

If you currently have or have previously had problems with your kidneys, talk to your doctor or hospital pharmacist as you may not be able to receive Pemetrexed Fresenius Kabi.

Before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive Pemetrexed Fresenius Kabi. Your doctor may decide to change the dose or delay treating you depending on your general condition and if your blood cell counts are too low. If you are also receiving cisplatin, your doctor will make sure that you are properly hydrated and receive appropriate treatment before and after receiving cisplatin to prevent vomiting.

If you have had or are going to have radiation therapy, please tell your doctor, as there may be an early or late radiation reaction with Pemetrexed Fresenius Kabi.

If you have been recently vaccinated, please tell your doctor, as this can possibly cause bad effects with Pemetrexed Fresenius Kabi.

If you have heart disease or a history of heart disease, please tell your doctor.

If you have an accumulation of fluid around your lungs, your doctor may decide to remove the fluid before giving you Pemetrexed Fresenius Kabi.

Children and adolescents

There is no relevant use of Pemetrexed Fresenius Kabi in the paediatric population

Other medicines and Pemetrexed Fresenius Kabi

Please tell your doctor if you are taking any medicine for pain or inflammation (swelling), such as medicines called “nonsteroidal anti-inflammatory drugs” (NSAIDs), including medicines purchased without a doctor’s prescription (such as ibuprofen). There are many sorts of NSAIDs with different durations of activity. Based on the planned date of your infusion of Pemetrexed Fresenius Kabi and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them. If you are unsure, ask your doctor or pharmacist if any of your medicines are NSAIDs.

Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

Pregnancy

If you are pregnant, , think you may be pregnant or are planning to have a baby, tell your doctor. The use of Pemetrexed Fresenius Kabi should be avoided during pregnancy. Your doctor will discuss with you the potential risk of taking Pemetrexed Fresenius Kabi during pregnancy. Women must use effective contraception during treatment with Pemetrexed Fresenius Kabi.

Breastfeeding

If you are breastfeeding, tell your doctor.

Breastfeeding must be discontinued during Pemetrexed Fresenius Kabi treatment.

Fertility

Men are advised not to father a child during and up to 6 months following treatment with Pemetrexed Fresenius Kabi and should therefore use effective contraception during treatment with Pemetrexed Fresenius Kabi and for up to 6 months afterwards. If you would like to father a child during the treatment or in the 6 months following receipt of treatment, seek advice from your doctor or pharmacist. You may want to seek counselling on sperm storage before starting your therapy.

Driving and using machines

Pemetrexed Fresenius Kabi may make you feel tired. Be careful when driving a car or using machines.

3.How to use Pemetrexed Fresenius Kabi

Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

The dose of Pemetrexed Fresenius Kabi is 500 milligrams for every square metre of your body’s surface area. Your height and weight are measured to work out the surface area of your body. Your doctor will use this body surface area to work out the right dose for you. This dose may be adjusted, or treatment may be delayed depending on your blood cell counts and on your general condition. A hospital pharmacist, nurse or doctor will have mixed the Pemetrexed Fresenius Kabi powder with 5% glucose intravenous infusion before it is given to you.

You will always receive Pemetrexed Fresenius Kabi by infusion into one of your veins. The infusion will last approximately 10 minutes.

When using Pemetrexed Fresenius Kabi in combination with cisplatin:

The doctor or hospital pharmacist will work out the dose you need based on your height and weight. Cisplatin is also given by infusion into one of your veins, and is given approximately 30 minutes after the infusion of Pemetrexed Fresenius Kabi has finished. The infusion of cisplatin will last approximately 2 hours.

You should usually receive your infusion once every 3 weeks.

Additional medicines:

Corticosteriods: your doctor will prescribe you steroid tablets (equivalent to 4 milligram of dexamethasone twice a day) that you will need to take on the day before, on the day of, and the day after Pemetrexed Fresenius Kabi treatment. This medicine is given to you to reduce the frequency and severity of skin reactions that you may experience during your anticancer treatment.

Vitamin supplementation: your doctor will prescribe you oral folic acid (vitamin) or a multivitamin containing folic acid (350 to 1000 micrograms) that you must take once a day while you are taking Pemetrexed Fresenius Kabi. You must take at least 5 doses during the seven days before the first dose of Pemetrexed Fresenius Kabi. You must continue taking the folic acid for 21 days after the last dose of Pemetrexed Fresenius Kabi. You will also receive an injection of vitamin B12

(1000 micrograms) in the week before administration of Pemetrexed Fresenius Kabi and then approximately every 9 weeks (corresponding to 3 courses of Pemetrexed Fresenius Kabi treatment). Vitamin B12 and folic acid are given to you to reduce the possible toxic effects of the anticancer treatment.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4.Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

You must contact your doctor immediately if you notice any of the following:

Fever or infection (common): if you have a temperature of 38ºC or greater, sweating or other signs of infection (since you might have less white blood cells than normal which is very common). Infection (sepsis) may be severe and could lead to death.

If you start feeling chest pain (common) or having a fast heart rate (uncommon).

If you have pain, redness, swelling or sores in your mouth (very common).

Allergic reaction: if you develop skin rash (very common) / burning or prickling sensation (common), or fever (common). Rarely, skin reactions may be severe and could lead to death. Contact your doctor if you get a severe rash, or itching, or blistering (Stevens-Johnson

Syndrome or Toxic epidermal necrolysis).

If you experience tiredness, feeling faint, becoming easily breathless or if you look pale (since you might have less haemoglobin than normal which is very common).

If you experience bleeding from the gums, nose or mouth or any bleeding that would not stop, reddish or pinkish urine, unexpected bruising (since you might have less platelets than normal which is very common).

If you experience sudden breathlessness, intense chest pain or cough with bloody sputum (uncommon)(may indicate a blood clot in the blood vessels of the lungs)

Side effects with Pemetrexed Fresenius Kabi may include:

Very common( may affect more than 1 in 10 people)

Low white blood cells

Low haemoglobin level (anaemia)

Low platelet count

Diarrhoea

Vomiting

Pain, redness, swelling or sores in your mouth

Nausea

Loss of appetite

Fatigue (tiredness)

Skin rash

Hair loss

Constipation

Loss of sensation

Kidney: abnormal blood tests

Common(may affect up to 1 in 10 people)

Allergic reaction: skin rash / burning or prickling sensation

Infection including sepsis

Fever

Dehydration

Kidney failure

Irritation of the skin and itching

Chest pain

Muscle weakness

Conjunctivitis (inflamed eye)

Upset stomach

Pain in the abdomen

Taste change

Liver: abnormal blood tests

Watery eyes

Uncommon (may affect up to 1 in 100 people)

Acute renal failure Fast heart rate

Inflammation of the lining of the oesophagus (gullet) has been experienced with Pemetrexed Fresenius Kabi / radiation therapy.

Colitis (inflammation of the lining of the large bowel, which may be accompanied by intestinal or rectal bleeding)

Interstitial pneumonitis (scarring of the air sacs of the lung)

Oedema (excess fluid in body tissue, causing swelling). Some patients have experienced a heart attack, stroke or “mini-stroke” while receiving Pemetrexed Fresenius Kabi usually in combination with another anticancer therapy.

Pancytopenia-combined low counts of white cells, red cells and platelets

Radiation pneumonitis (scarring of the air sacs of the lung associated with radiation therapy) may

occur in patients who are also treated with radiation either before, during or after their Pemetrexed Fresenius Kabi therapy.

Extremity pain, low temperature and discolouration have been reported. Blood clots in the lung blood vessels (pulmonary embolism)

Rare (may affect up to 1 in 1,000 people)

Radiation recall (a skin rash like severe sunburn) which can occur on skin that has previously been exposed to radiotherapy, from days to years after the radiation.

Bullous conditions (blistering skin diseases)-including Stevens-Johnson syndrome and Toxic epidermal necrolysis

Immune mediated haemolytic anaemia (antibody-mediated destruction of red blood cells) Hepatitis (inflammation of the liver)

Anaphylactic shock (severe allergic reaction)

Not known: frequency cannot be estimated from the available data

Lower limb swelling with pain and redness

You might have any of these symptoms and/or conditions. You must tell your doctor as soon as possible when you start experiencing any of these side effects.

If you are concerned about any side effects, talk to your doctor.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in the leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5.How to store Pemetrexed Fresenius Kabi

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and carton.

This medicine does not require any special storage conditions.

Reconstituted and infusion solutions: The product should be used immediately. When prepared as directed, chemical and physical in-use stability of reconstituted and infusion solutions of pemetrexed were demonstrated for 24 hours at refrigerated temperature.

This medicine should not been used if there are any signs of particles.

This medicine is for single use only.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Pemetrexed Fresenius Kabi contains

The active substance is pemetrexed.

Pemetrexed Fresenius Kabi 100 mg: Each vial contains 100 milligrams of pemetrexed (as

pemetrexed diacid).

Pemetrexed Fresenius Kabi 500 mg: Each vial contains 500 milligrams of pemetrexed (as pemetrexed diacid).

After reconstitution, the solution contains 25 mg/ml of pemetrexed. Further dilution by a healthcare provider is required prior to administration.

The other ingredients are mannitol, hydrochloric acid concentrated and trometamol.

What Pemetrexed Fresenius Kabi looks like and contents of the pack

Pemetrexed Fresenius Kabi is a powder for concentrate for solution for infusion in a glass vial. It is a white to off-white lyophilised powder or solid.

Each pack consists of one vial.

Marketing Authorisation Holder and Manufacturer

Fresenius Kabi Oncology Plc.

Lion Court, Farnham Road, Bordon

Hampshire, GU35 0NF

United Kingdom

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.

België/Belgique/Belgien

Lietuva

Fresenius Kabi nv

Fresenius Kabi Baltics UAB

Tél/Tel: +32 (0)3 880 73 00

Tel: +370 52609169

България

Luxembourg/Luxemburg

Fresenius Kabi Bulgaria EOOD

Fresenius Kabi Deutschland GmbH

Teл.: + 359 (0) 2 971 02 63

Tél/Tel: +49 (0)6172 686 0

Česká republika

Magyarország

Fresenius Kabi s.r.o.

Fresenius Kabi Hungary Kft.

Tel: + 420 2 25 27 0111

Tel.: + 36 1 250 8371

Denmark

Malta

Fresenius Kabi

Fresenius Kabi Limited

Tlf: + 45 33 18 16 00

Tel: +44 (0) 1928 533 533

Deutschland

Nederland

Fresenius Kabi Deutschland GmbH

Fresenius Kabi Nederland BV

Tel: +49 (0)6172 686 0

Tel: +31 (0)30 698 52 70

Eesti

Norge

KBM Pharma OÜ

Fresenius Kabi Norge AS

Tel: +372 733 8080

Tlf: + 47 69211100

Ελλάδα

Österreich

Fresenius Kabi Hellas A.E.

Fresenius Kabi Austria GmbH

Τηλ: + 0030 210 6542909

Tel: +43 316 249 0

España

Polska

Fresenius Kabi España S.A.U

Fresenius Kabi Polska Sp. z o.o.

Tel: + 932256580

Tel.: + 0048 22 345 67 89

France

Portugal

Fresenius Kabi France

Fresenius Kabi Pharma Portugal, Lda

Tél: +33 1 41 14 26 00.

Tel: + 351 21 424 1280

Hrvatska

România

Fresenius Kabi d.o.o.

S.C. Fresenius Kabi România S.R.L.

Tel: +385 1 2333 242

Tel: + 40 (0)268 40 62 60

Ireland

Slovenija

Fresenius Kabi Limited

Medias International d.o.o.

Tel: +44 (0) 1928 533 533

Tel: + 386 (0)1 52 02 300

Ísland

Slovenská republika

Fresenius Kabi

Fresenius Kabi s.r.o.

Sími: + 45 33 18 16 00

Tel: + +421 244 633 727

Italia

Suomi/Finland

Fresenius Kabi Italia S.r.l

Fresenius Kabi Ab

Tel: + 39 045 6649311

Puh/Tel: + 358 9 4281 550

Κύπρος

Sverige

Fresenius Kabi Hellas A.E

Fresenius Kabi AB

Τηλ: + 0030 210 6542909

Tel: +46 18 644000

Latvija

United Kingdom

KBM Pharma SIA

Fresenius Kabi Limited

Tel: +371 67103113

Tel: +44 (0) 1928 533 533

This leaflet was last revised in

Other sources of information

Detailed information on this product is available on the website of European Medicinal Agency http://www.ema/europa.eu

<---------------------------------------------------------------------------------------------------------------

The following information is intended for medical or healthcare professionals only:

Instructions for use, handling and disposal.

1.Use aseptic techniques during the reconstitution and further dilution of pemetrexed for intravenous infusion administration.

2.Calculate the dose and the number of Pemetrexed Fresenius Kabi vials needed. Each vial contains an excess of pemetrexed to facilitate delivery of the label amount.

3.Pemetrexed Fresenius Kabi 100 mg:

Reconstitute each 100 mg vial with 4.2 ml of 5% glucose intravenous infusion resulting in a solution containing 25 mg/ml pemetrexed.

Pemetrexed Fresenius Kabi 500 mg:

Reconstitute each 500 mg vial with 20 ml of 5% glucose intravenous infusion resulting in a solution containing 25 mg/ml pemetrexed.

Gently swirl each vial until the powder is completely dissolved. The resulting solution is clear and ranges in colour from colourless to yellow or green-yellow without adversely affecting product quality. The pH of the reconstituted solution is between 6.6 and 7.8. Further dilution is required.

4.The appropriate volume of reconstituted pemetrexed solution must be further diluted to 100 ml with 5% glucose intravenous infusion and administered as an intravenous infusion over 10 minutes.

5.Pemetrexed infusion solutions prepared as directed above are compatible with polyvinyl chloride and polyolefin lined administration sets and infusion bags. Pemetrexed is incompatible with diluents containing calcium, including lactated Ringer’s Injection and Ringer’s Injection.

6.Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration. If particulate matter is observed, do not administer.

7.Pemetrexed solutions are for single use only. Any unused product or waste material should be disposed of in accordance with local requirements.

Preparation and administration precautions: As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of pemetrexed infusion solutions. The use of gloves is recommended. If a pemetrexed solution contacts the skin, wash the skin immediately and thoroughly with soap and water. If pemetrexed solutions contact the mucous membranes, flush thoroughly with water. Pregnant women must avoid contact with cytostatic medicinal product. Pemetrexed is not a vesicant. There is not a specific antidote for extravasation of pemetrexed. There have been a few reported cases of pemetrexed extravasation, which were not assessed as serious by the investigator. Extravasation should be managed by local standard practice as with other non-vesicants.

Comments

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Help
  • Get it on Google Play
  • About
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    prescription drugs listed